Circular Genomics is pioneering advancements in precision psychiatry through its innovative use of circular RNA (circRNA) biomarkers. These unique molecules, which are particularly abundant and stable in the brain, are generated through the backsplicing of precursor mRNAs. Their stability and ability to cross the blood-brain barrier make them ideal candidates for diagnostic and predictive biomarkers in psychiatric and neurological disorders. Circular Genomics focuses on the development of tests that leverage these biomarkers to enhance the diagnosis and treatment of conditions such as Major Depressive Disorder (MDD) and Alzheimer's disease. By utilizing circRNAs, the company aims to provide real-time insights into an individual's biological state, thereby improving treatment selection and patient outcomes.

One of the flagship products of Circular Genomics is the MindLight Antidepressant Response Test, which is the first-ever circular RNA-based test designed to predict a patient's response to selective serotonin reuptake inhibitors (SSRIs). This test addresses the limitations of the traditional trial-and-error approach in psychiatric treatment by offering a more streamlined and evidence-based method for selecting appropriate therapies. The MindLight test has demonstrated a diagnostic accuracy of 77% in predicting SSRI response among MDD patients, showcasing the potential of circRNA biomarkers to transform mental healthcare. Through ongoing research and development, Circular Genomics is committed to enhancing the understanding and treatment of mental health disorders, ultimately aiming to shift the paradigm in psychiatric care.

United States

Circular Genomicsis abiotechnology and genomics company with a vision to use circular RNAs as novel and improved biomarkers for the diagnosis and better treatment of psychiatric and neurological diseases

Circular Genomics

Company Details